Clinically reviewed by Mohammed Ismail Lakhi, MPharm, MRPharmS — Superintendent Pharmacist (GPhC reg. 2072815)
Last updated: April 2026
Key points at a glance
Orforglipron is a once-daily oral GLP-1 receptor agonist developed by pharmaceutical company Eli Lilly. In the United States, it has been approved by the Food and Drug Administration under the brand name Foundayo, making it the first small-molecule GLP-1 weight loss pill of its kind to reach market. For anyone searching “Orforglipron UK” hoping it is already available here, the short answer is that it is not yet licensed by the MHRA — but a UK launch is anticipated, and this guide covers everything you need to know.
Like its injectable siblings Wegovy and Mounjaro, Orforglipron belongs to the GLP-1 receptor agonist family of medicines. These drugs work by mimicking a natural gut hormone called glucagon-like peptide-1, which regulates appetite, slows stomach emptying, and helps control blood sugar levels. The result is reduced hunger, earlier fullness at meals, and — when combined with lifestyle changes — meaningful, sustained weight loss.
What makes Orforglipron genuinely different is how it is taken. Existing GLP-1 medicines like Mounjaro and Wegovy are peptide-based, which means they would be broken down by stomach acid if swallowed — so they have to be injected. Orforglipron is a non-peptide small molecule, which is stable enough to survive digestion. That single structural difference unlocks the first needle-free, once-daily pill in this drug class with no food or water restrictions, which is exactly what many patients have been waiting for.
This is the question most people searching for Orforglipron UK information really want answered, so let us be direct: Orforglipron is not yet licensed in the UK. As of April 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) has not yet granted approval, and no licensed UK pharmacy can legally supply it. Any online provider claiming to sell Orforglipron in the UK today is operating outside the law and should be avoided.
Eli Lilly has confirmed that it has submitted Orforglipron for regulatory approval in more than 40 countries, including the UK, and plans to launch in each market shortly after clearance. The likely UK timeline, based on typical MHRA review durations and the sequence already seen with Mounjaro and Wegovy, looks like this:
Mid to late 2026: MHRA regulatory review ongoing following submission.
Late 2026 to 2027: Potential MHRA approval and private pharmacy availability.
2027 and beyond: NICE assessment for possible NHS availability, likely for restricted patient groups.
These timelines are indicative. Regulatory reviews can be faster or slower depending on the evidence package and any follow-up questions from the MHRA.
It is worth noting that the FDA approved Foundayo under an expedited national priority voucher pathway, achieving approval roughly 294 days ahead of its original target date. The MHRA does not operate an identical scheme, so UK patients should expect a more standard review timeline rather than a similarly accelerated one.
Orforglipron works by activating GLP-1 receptors throughout the body, mimicking the action of your natural gut hormones released after eating. Once activated, these receptors trigger several effects that work together to support weight loss:
Because Orforglipron is a small molecule rather than a peptide, its absorption is not disrupted by food or water in the stomach. This means it can be taken at any time of day, with or without a meal — a practical advantage over other oral GLP-1 options and a reason many clinicians view it as a genuinely patient-friendly formulation.
Orforglipron has been studied in the ATTAIN phase 3 clinical trial programme, which involved thousands of adults with obesity or overweight with weight-related medical conditions. The headline findings from the trial data are:
These results place Orforglipron in a middle position within the current GLP-1 landscape. It is more effective than older oral weight loss medicines such as orlistat, broadly comparable to Wegovy injections in terms of average weight loss, but generally less powerful than Mounjaro at its highest 15 mg dose, where the SURMOUNT-1 trial reported average weight loss of approximately 20–21% over 72 weeks.
For UK patients weighing up options now and in the future, here is how Orforglipron stacks up against the two MHRA-approved GLP-1 injections currently available through The Care Pharmacy:
| Feature | Orforglipron (Foundayo) | Mounjaro (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|---|
| Format | Once-daily oral tablet | Once-weekly injection | Once-weekly injection |
| Drug class | Non-peptide GLP-1 agonist | Dual GIP/GLP-1 agonist | GLP-1 agonist (peptide) |
| Average weight loss | ~11–12.4% at 72 weeks | Up to ~20–21% at 15 mg dose | ~14–17% at 68 weeks |
| Food/water restrictions | None — any time of day | None | None for injection |
| UK availability | Not yet approved | Available privately from £149.99 | Available privately |
| Manufacturer | Eli Lilly | Eli Lilly | Novo Nordisk |
The choice between these options will ultimately come down to personal preference, clinical suitability, and what is available in the UK at the time you begin treatment. For patients who are ready to start a weight loss journey now, Mounjaro and Wegovy remain the two most clinically proven GLP-1 medicines available in the UK.
The safety profile of Orforglipron in clinical trials has been broadly consistent with other GLP-1 receptor agonists. The most commonly reported side effects were gastrointestinal, and most were mild to moderate and tended to improve as the body adjusted to treatment or between dose increases.
As with other GLP-1 medicines, rare but potentially serious risks include pancreatitis, gallbladder problems (including gallstones), acute kidney injury linked to dehydration from prolonged vomiting or diarrhoea, and severe hypersensitivity reactions. In patients with type 2 diabetes, there is also an increased risk of hypoglycaemia when Orforglipron is used alongside insulin or sulfonylureas. The FDA label for Foundayo also carries a warning that it may cause thyroid tumours, including medullary thyroid carcinoma, based on findings from animal studies. It must not be used in patients with a personal or family history of medullary thyroid carcinoma, or those with multiple endocrine neoplasia syndrome type 2 (MEN2).
Important: Any GLP-1 medicine — whether a pill or an injection — should only be used under the supervision of a qualified prescribing clinician, following a proper medical consultation. Self-sourcing unlicensed or counterfeit medicines from unregulated online sellers is both illegal and genuinely dangerous.
Orforglipron, like other GLP-1 receptor agonists, is not suitable during pregnancy or breastfeeding. If you are planning a pregnancy, you should discuss stopping treatment with your prescriber well in advance — current guidance for GLP-1 receptor agonists generally recommends discontinuation at least two months before conception. If you become pregnant while taking a GLP-1 medicine, contact your prescriber promptly for advice.
GLP-1 receptor agonists slow the rate at which food leaves the stomach, which can affect how other oral medicines are absorbed — including oral contraceptives. If you rely on the combined pill or progestogen-only pill for contraception, discuss this with your prescriber before starting treatment, as additional contraceptive precautions may be recommended. Always share a full list of your current medicines, including over-the-counter products and supplements, at your consultation.
Orforglipron has been studied, and in the United States approved, for adults with obesity or adults who are overweight with at least one weight-related medical condition. In practical terms, once Orforglipron becomes available in the UK, eligibility criteria are likely to follow the same pattern as other weight loss medications currently prescribed here:
An oral GLP-1 pill like Orforglipron may be particularly appealing for:
However, Orforglipron will not be suitable for everyone. People with certain thyroid cancer histories, previous pancreatitis, severe gastrointestinal disorders, or those who are pregnant, breastfeeding or planning pregnancy will typically not be candidates for GLP-1 treatment. A clinical consultation is the only reliable way to find out whether this class of medicine is appropriate for you.
Pricing for Orforglipron in the UK has not been set, because the medicine is not yet licensed here. Private pricing will only be confirmed once the MHRA approval process is complete and the manufacturer sets its list price for the UK market.
That said, a useful frame of reference comes from the US launch. Foundayo has been positioned as a more accessible GLP-1 option, with early US pricing reportedly set below the cost of injectable GLP-1s. Small-molecule pills are generally cheaper to manufacture than complex peptide injections, so there is a reasonable expectation that Orforglipron may eventually prove more cost-accessible than Mounjaro or Wegovy in the UK as well.
Whether Orforglipron is funded on the NHS is a separate question. After MHRA licensing, the National Institute for Health and Care Excellence (NICE) would need to assess cost-effectiveness before any NHS availability. Based on the pattern with Mounjaro and Wegovy, it is realistic to expect that Orforglipron would be available privately first, with any NHS availability following later and likely limited to specific patient groups.
If you have read this far, you are likely considering whether to wait for Orforglipron or start a clinically proven weight loss treatment now. For most patients who meet the eligibility criteria, there is little benefit in waiting — the MHRA-approved alternatives already available deliver comparable or greater weight loss, have years of real-world safety data behind them, and can be accessed through regulated UK pharmacies.
Currently the most effective MHRA-approved weight loss injection, made by the same pharmaceutical company behind Orforglipron. Mounjaro is a dual GIP/GLP-1 receptor agonist, offering average weight loss of approximately 20–21% at the highest 15 mg dose in clinical trials. Administered as a weekly injection using a simple pre-filled pen.
At The Care Pharmacy, Mounjaro starts from £149.99.
The established GLP-1 weight loss injection from Novo Nordisk, with a substantial body of published clinical and real-world evidence. Wegovy typically helps patients achieve average weight loss in the region of 14–17% across the trial programme, also administered as a once-weekly injection. Widely used in the UK since its launch and a trusted choice for many clinicians.
Wegovy is available privately through The Care Pharmacy following a clinical consultation.
Both of these treatments are fully licensed for weight management in the UK, supplied through GPhC-registered pharmacies, and backed by substantial phase 3 clinical trial programmes. Crucially, they are available now — not in a theoretical future — which matters when every month spent waiting is a month of lost progress toward better health.
No. Orforglipron is not currently licensed or legally available anywhere in the UK. Any UK-based website or provider offering Orforglipron or Foundayo for sale today is operating outside the law, and the product they supply cannot be verified as safe, genuine, or correctly dosed. Waiting for MHRA approval and purchasing through a regulated UK pharmacy is the only safe route.
No. Although all three belong to the GLP-1 receptor agonist family, they are distinct medicines. Orforglipron is an oral once-daily pill developed by Eli Lilly as a non-peptide small molecule. Mounjaro (tirzepatide), also made by Eli Lilly, is a weekly injection that activates both GLP-1 and GIP receptors. Wegovy (semaglutide) is a weekly injection made by Novo Nordisk. They differ in how they are taken, their molecular structure, and the average weight loss achieved in clinical trials.
It is too early to say. Even after MHRA approval, the National Institute for Health and Care Excellence (NICE) will need to assess whether Orforglipron is clinically and cost-effective for NHS use. Based on how Mounjaro and Wegovy have been handled, any NHS availability is likely to be restricted to specific patient groups, with private prescription through regulated pharmacies remaining the faster route for most patients.
In terms of average weight loss, current head-to-head trial comparisons have not been published, but based on separate trial data Mounjaro appears to produce greater average weight loss at its highest 15 mg dose (approximately 20–21%) compared with Orforglipron (around 11–12.4%). However, “better” is personal. Orforglipron offers the convenience of a daily tablet with no food or water restrictions, which may outweigh the smaller weight loss figure for patients who strongly prefer avoiding injections. A clinical consultation is the best way to decide what is right for your situation.
For most patients, there is little clinical reason to wait. Mounjaro and Wegovy are MHRA-approved, well-studied, and available through regulated UK pharmacies now. Delaying treatment by a year or more to wait for a medicine with a slightly different delivery format — but on average somewhat lower weight loss — rarely makes sense when excess weight is already contributing to health risks. If and when Orforglipron does become available in the UK, switching treatment after discussion with your prescriber is always an option.
Clinical trials in the ACHIEVE programme have shown Orforglipron can meaningfully reduce HbA1c and fasting blood glucose in people with type 2 diabetes, with results that appear broadly comparable to other GLP-1 receptor agonists, though direct head-to-head data against specific comparators remain limited. However, its FDA approval to date is for chronic weight management. Eli Lilly has submitted Orforglipron for type 2 diabetes approval in multiple countries, so an additional licensed indication for diabetes is anticipated in future. In the UK, any use for type 2 diabetes will depend on MHRA licensing decisions.
Orforglipron (Foundayo) is a genuine milestone in obesity medicine — the first small-molecule GLP-1 weight loss pill, taken once a day with no food or water restrictions, and delivering meaningful weight loss in clinical trials. For patients who have been holding out for a pill-based option, it is real, it works, and it is coming.
For UK patients specifically, though, the reality is that Orforglipron is not yet licensed by the MHRA and is unlikely to be legally available here until late 2026 or into 2027 at the earliest. If you are searching for “Orforglipron UK” because you want to start now, the honest answer is that you have two options: wait, or begin treatment with a fully licensed, clinically proven alternative like Mounjaro or Wegovy — both available right now through The Care Pharmacy following a proper clinical consultation.
At The Care Pharmacy, we are a GPhC-registered UK pharmacy specialising in weight management. Our prescribing clinicians will review your consultation, confirm clinical suitability, and guide you through treatment with ongoing support. And when Orforglipron does eventually receive UK approval, we will be ready to offer it as another option for the patients we serve.
Begin a free, confidential online consultation with our pharmacist-led team. Mounjaro from £149.99. Wegovy also available.
This article was clinically reviewed by Mohammed Ismail Lakhi, MPharm, MRPharmS, Superintendent Pharmacist at The Care Pharmacy. Mohammed is registered with the General Pharmaceutical Council (GPhC registration number 2072815) and leads clinical governance across The Care Pharmacy’s weight management services.
Disclaimer: This article is for general information only and is not a substitute for individual medical advice. Orforglipron (Foundayo) is not licensed for use in the UK at the time of publication. Do not purchase Orforglipron from any UK-based seller until it has received MHRA approval. Always consult a qualified prescriber before starting any prescription weight loss treatment.
Medically reviewed by
Superintendent Pharmacist
The most common question we hear from patients is: Wegovy vs Mounjaro — which one should I choose? This honest, pharmacist-written guide covers clinical trial data, the new Wegovy 7.2mg dose, real-world UK pricing, side effects, NHS access, and how to decide which weight loss injection suits your goals. Updated: March 2026 · 16 min […]
Orlistat is one of the most established prescription weight loss medications available in the UK. Despite its long history, many people still ask the same question: does Orlistat burn fat, or does it simply block fat absorption? A clear understanding of its mechanism can make it easier to manage expectations and optimise success. The Care […]
If you are exploring prescription weight management options and wondering whether Xenical or a weight loss injectable is right for you, our clinical team can help. At The Care Pharmacy, we offer a range of medically approved weight loss treatments, including Xenical and several injectable options. The right choice depends on your health profile, weight […]
If you are using Saxenda in the UK and planning to fast during Ramadan, it is important to understand how to manage your treatment safely. Our pharmacy team can review your situation and help you make informed decisions. Ramadan brings changes to meal timing, hydration, sleep, and daily routine. For Saxenda users, these changes can […]
If you are looking for a clinically supported way to lose weight, Orlistat can be a helpful option for many people in the UK. It is one of the most established prescription weight loss treatments and works differently to newer appetite-suppressing injections. Instead of changing hunger hormones, Orlistat helps reduce the amount of fat your […]
If you are researching the best weight loss capsules, you are not alone. Many people begin their weight loss journey by looking for tablets or capsules before considering injectable treatments. At The Care Pharmacy, we support patients across the UK with honest, clinically led advice so they can understand which options are most effective, safe, […]
